Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5281841
Max Phase: Preclinical
Molecular Formula: C23H27N9O7
Molecular Weight: 541.53
Associated Items:
ID: ALA5281841
Max Phase: Preclinical
Molecular Formula: C23H27N9O7
Molecular Weight: 541.53
Associated Items:
Canonical SMILES: CCCNC(=O)[C@H](CNC(=O)Cn1cc(C(N)=O)c(=O)[nH]c1=O)NC(=O)CCc1nc(-c2cccnc2)no1
Standard InChI: InChI=1S/C23H27N9O7/c1-2-7-26-22(37)15(10-27-17(34)12-32-11-14(19(24)35)21(36)30-23(32)38)28-16(33)5-6-18-29-20(31-39-18)13-4-3-8-25-9-13/h3-4,8-9,11,15H,2,5-7,10,12H2,1H3,(H2,24,35)(H,26,37)(H,27,34)(H,28,33)(H,30,36,38)/t15-/m0/s1
Standard InChI Key: WGTNFHHLZQGSEM-HNNXBMFYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 541.53 | Molecular Weight (Monoisotopic): 541.2033 | AlogP: -2.16 | #Rotatable Bonds: 13 |
Polar Surface Area: 237.06 | Molecular Species: NEUTRAL | HBA: 11 | HBD: 5 |
#RO5 Violations: 2 | HBA (Lipinski): 16 | HBD (Lipinski): 6 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 8.96 | CX Basic pKa: 3.67 | CX LogP: -2.47 | CX LogD: -2.48 |
Aromatic Rings: 3 | Heavy Atoms: 39 | QED Weighted: 0.16 | Np Likeness Score: -1.73 |
1. Fiorentino F, Mai A, Rotili D.. (2021) Emerging Therapeutic Potential of SIRT6 Modulators., 64 (14.0): [PMID:34213345] [10.1021/acs.jmedchem.1c00601] |
Source(1):